Market Cap | 6.82M | P/E | - | EPS this Y | 52.50% | Ern Qtrly Grth | - |
Income | -3.63M | Forward P/E | - | EPS next Y | -25.00% | 50D Avg Chg | 2.00% |
Sales | 72.1k | PEG | - | EPS past 5Y | - | 200D Avg Chg | -18.00% |
Dividend | N/A | Price/Book | 0.72 | EPS next 5Y | - | 52W High Chg | -82.00% |
Recommedations | 2.00 | Quick Ratio | 9.88 | Shares Outstanding | 2.84M | 52W Low Chg | 1,171.00% |
Insider Own | 6.35% | ROA | -24.86% | Shares Float | 2.54M | Beta | 1.34 |
Inst Own | 5.65% | ROE | -43.97% | Shares Shorted/Prior | 115.03K/50.72K | Price | 2.16 |
Gross Margin | 91.90% | Profit Margin | - | Avg. Volume | 147,167 | Target Price | 10.00 |
Oper. Margin | -5,347.41% | Earnings Date | - | Volume | 325,213 | Change | 0.93% |
Silo Pharma. Inc., a developmental stage biopharmaceutical company, develops traditional therapeutics and psychedelic medicine. Its lead program includes SPC-15, an intranasal drug targeting post-traumatic stress disorder (PTSD) and stress-induced anxiety disorders; and SP-26, a ketamine-based loaded implant indicated for fibromyalgia and chronic pain relief. The company's preclinical products include SPC-14 to treat Alzheimer's disease; and SPU-16, a central nervous system homing peptide targeting the central nervous system with indication in multiple sclerosis. It also seeks to acquire and/or develop intellectual property or technology rights from universities and researchers to treat rare diseases, including the use of psychedelic drugs, such as psilocybin and ketamine, as well as depression, mental health issues, and neurological disorders. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is based in Sarasota, Florida.
Laidlaw & Co. | Buy | Aug 28, 23 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Weisblum Eric | CEO and President CEO and President | Dec 14 | Buy | 1.51 | 1,100 | 1,661 | 169,224 | 12/18/23 |
Weisblum Eric | CEO and President CEO and President | Dec 05 | Buy | 1.36 | 1,000 | 1,360 | 168,124 | 12/07/23 |
Weisblum Eric | CEO and President CEO and President | Nov 29 | Buy | 1.55 | 2,000 | 3,100 | 167,124 | 11/30/23 |
Weisblum Eric | CEO and President CEO and President | Nov 22 | Buy | 1.73 | 650 | 1,124 | 165,124 | 11/27/23 |
Weisblum Eric | CEO and President CEO and President | Nov 16 | Buy | 1.44 | 2,900 | 4,176 | 160,124 | 11/20/23 |
Weisblum Eric | CEO and President CEO and President | Dec 19 | Buy | 2.7 | 330 | 891 | 154,854 | 12/20/22 |
Weisblum Eric | CEO, CFO and Preside.. CEO, CFO and President | Jun 17 | Buy | 0.1147 | 13,080 | 1,500 | 7,724,643 | 06/21/22 |